Company / EPS (Diluted)
Inmune Bio, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.11
FY2025
5-year range
-$2.11 / -$1.01
FY2021-FY2025
Trend
-26.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $-1.52 to $-2.11 over the past 2 years.
Based on SEC 10-K filings.
-2.11 in FY2025.
Declined from $-1.52 to $-2.11 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 26.3% year-over-year.
- Peak eps (diluted) was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.11 | -26.3% |
| FY2024 | -$1.67 | -9.9% |
| FY2023 | -$1.52 | +19.1% |
| FY2022 | -$1.88 | -86.1% |
| FY2021 | -$1.01 | -34.7% |
| FY2020 | -$0.75 | -476.9% |
| FY2018 | -$0.13 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026